THE NEW YORK TIMES COMPANY Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount
THE NEW YORK TIMES COMPANY (NYT) reported Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount of $4.06 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount · last filed 2026-02-27
- THE NEW YORK TIMES COMPANY equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2025-12-31 was $562.00K.
- THE NEW YORK TIMES COMPANY equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2025-09-30 was $3.50M.
- THE NEW YORK TIMES COMPANY equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2024-12-31 was $0.00.
- THE NEW YORK TIMES COMPANY equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2024-09-30 was $0.00.
- THE NEW YORK TIMES COMPANY equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2025 was $4.06M.
- THE NEW YORK TIMES COMPANY equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2024 was $0.00.
- THE NEW YORK TIMES COMPANY equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2023 was $0.00.
| Period end | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 3 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 6 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 9 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 12 month |
|---|---|---|---|---|
| 2025-12-31 | $562.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $4.06M derived: sum of 2 quarters · filed 2026-02-27 | $4.06M 10-K · filed 2026-02-27 | |
| 2025-09-30 | $3.50M 10-Q · filed 2025-11-05 | $3.50M 10-Q · filed 2025-11-05 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $0.00 derived: sum of 2 quarters · filed 2026-02-27 | $0.00 10-K · filed 2026-02-27 | |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | ||
| 2023-12-31 | $0.00 10-K · filed 2026-02-27 |